Wall Street analyst estimates for SELLAS Life Sciences Group, Inc. (SLS): consensus price target and buy/hold/sell recommendations.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-0.05 | ||
| 2026-08-11 | $-0.05 | $-0.04 | -11.1% |
| 2026-05-12 | $-0.05 | $-0.06 | +16.7% |
| 2026-03-19 | $-0.05 | $-0.06 | +21.0% |
| 2025-11-12 | $-0.06 | $-0.06 | +5.3% |
| 2025-08-12 | $-0.07 | $-0.08 | +16.0% |
| 2025-05-13 | $-0.07 | $-0.10 | +30.0% |
| 2025-03-20 | $-0.08 | $-0.11 | +27.3% |
Valuation Ratios
| Price / Book | 15.27 |
| EV / EBITDA | -91.42 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $1.9M | $7.6M | $1.0M | 0 | 0 | 0 |
| Cost of Revenue | $3,000 | 0 | 0 | 0 | 0 | $200,000 | $100,000 | 0 | 0 | 0 |
| Gross Profit | -$3,000 | 0 | 0 | 0 | $1.9M | $7.4M | $900,000 | 0 | 0 | 0 |
| Research & Development | $19.9M | $6.1M | $18.3M | $10.1M | $9.3M | $21.4M | $30.3M | $24.0M | $19.1M | $16.0M |
| Selling, General & Admin | $12.0M | $15.1M | $12.8M | $9.9M | $9.6M | $11.3M | $12.6M | $13.9M | $12.4M | $12.3M |
| Operating Expenses | $31.9M | $21.2M | $31.6M | $20.0M | $18.9M | $32.7M | $42.9M | $37.9M | $31.5M | $28.3M |
| Operating Income | -$16.0M | -$15.7M | -$31.6M | -$20.0M | -$17.0M | -$25.3M | -$42.0M | -$37.9M | -$31.5M | -$28.3M |
| EBITDA | -$16.0M | -$22.8M | -$6.7M | 0 | -$16.5M | -$18.3M | -$31.5M | $529,000 | $632,000 | -$26.9M |
| Interest Expense | $3.5M | $462,000 | $266,000 | $118,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$17.7M | -$23.5M | -$29.0M | -$19.4M | -$16.8M | -$20.9M | -$41.3M | -$37.3M | -$30.9M | -$26.9M |
| Income Tax | $243,000 | $253,000 | -$1.4M | -$81,000 | -$17,000 | -$237,000 | 0 | 0 | 0 | 0 |
| Net Income | -$23.5M | -$23.8M | -$27.7M | -$19.3M | -$16.8M | -$20.7M | -$41.3M | -$37.3M | -$30.9M | -$26.9M |
| EPS | $-933.13 | $-521.91 | $-157.72 | $-10.92 | $-2.11 | $-1.34 | $-2.13 | $-1.34 | $-0.50 | $-0.25 |
| EPS (Diluted) | $-933.13 | $-521.91 | $-157.72 | $-10.92 | $-2.11 | $-1.34 | $-2.13 | $-1.34 | $-0.50 | $-0.25 |
| Shares Outstanding (Diluted) | 18,948 | 46,807 | 261,542 | 2.6 M | 8.0 M | 15.5 M | 19.4 M | 27.8 M | 61.2 M | 109.1 M |
Price
| Price | $10.38 (closing price, October 28, 2026) |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: INCY · IDYA · IMNM · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SLS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks